Posted by Michael Wonder on 02 Jan 2024
Beyfortus approved in China for the prevention of RSV disease in infants
2 January 2024 - First and only RSV preventive option authorised for use in China
AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in China for the prevention of respiratory syncytial virus (RSV) lower respiratory tract infection in neonates and infants entering or during their first RSV season.
